Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Israeli Stocks: Teva, Elbit Imaging, Cellcom, Partner, Kamada

April 1 (Bloomberg) -- Israel’s TA-25 index advanced for the first time in three days, gaining 0.4 percent to 1,129.43 at the 4:30 p.m. close in Tel Aviv. Investors traded about 531.6 million shekels ($143 million) of shares and convertible securities, according to bourse data.

The following stocks rose or fell today. Symbols are in parentheses.

Cellcom Israel Ltd. (CEL IT), Israel’s largest mobile-phone provider, declined 3.6 percent, to 45.30 shekels, the lowest level on record. Partner Communications Ltd. (PTNR IT), the country’s second biggest mobile-phone company, fell 3.4 percent to 27.65 shekels. “They are in a very competitive market and if they raise prices they will lose market share,” said Ilanit Sherf, an analyst at Psagot Investment House Ltd.

Elbit Imaging Ltd. (EMIT IT) advanced 4.5 percent, the most since March 26, to 10 shekels, giving the company a market value of 249 million shekels. The real estate investor said it will post a gain of about 180 million shekels from the sale of four hotels in the Netherlands.

Kamada Ltd. (KMDA IT) advanced 4.7 percent to 22.40 shekels, the highest close since Nov. 13, giving the Nes Ziona, Israel-based company a market value of 619 million shekels. Revenue this year will be 257 million shekels after 213 million shekels in 2011, the pharmaceutical company forecast.

Teva Pharmaceutical Industries Ltd. (TEVA IT) advanced 2.9 percent, the biggest jump since Jan. 4, to 168.80 shekels. The world’s largest maker of generic drugs said it started shipping the authorized generic of Provigil, marketed by its Cephalon Inc. subsidiary.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.